OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,720.00
+230.00 (4.19%)
At close: Jun 9, 2026
Market Cap102.35B -1.2%
Revenue (ttm)91.62B +11.8%
Net Income12.70B +39.8%
EPS796.92 +34.0%
Shares Out 17.65M
PE Ratio7.28
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume118,235
Open5,590.00
Previous Close5,490.00
Day's Range5,550.00 - 5,800.00
52-Week Range5,440.00 - 20,750.00
Beta-0.07
Analystsn/a
Price Targetn/a
Earnings DateJan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 159
Stock Exchange KOSDAQ
Ticker Symbol 131030
Full Company Profile

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.

Financial Statements